Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited has announced a change in the interest of its director, James Garner, with the acquisition of 5,000,000 unquoted options. These options were issued under the company’s Bonus Offer, as detailed in their prospectus filed with ASIC and ASX in early May 2025. This move reflects strategic financial adjustments and may influence the company’s market positioning and stakeholder interests.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 4,227,335
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.